Clover Health Investments Corp Stock Price, News & Analysis

Clover Health (NASDAQ: CLOV) reported Q3 2025 results: Medicare Advantage membership 109,226 (+35% YoY) and Total revenues $496.7M (+50% YoY). Q3 profitability metrics: GAAP net loss $24.4M, Adjusted EBITDA $2.1M, and Adjusted Net income $1.7M. Year-to-date Adjusted EBITDA is $45.0M and Adjusted Net income is $43.7M. Cash and investments totaled $395.9M (down 25.5% YoY). Q3 Insurance BER rose to 93.5% from 82.8% a year earlier; Normalized Insurance BER was 92.4%.

The company raised full‑year 2025 guidance: Avg. MA membership 106k–108k, Insurance revenue $1.85B–$1.88B, Adjusted SG&A $325M–$335M, and Adjusted EBITDA $15M–$30M. Management cited cohort economics, retention, and a favorable 2026 CMS environment as drivers toward improved profitability.

Clover Health (Nasdaq: CLOV) announced that Chelsea Clinton will step down from its Board of Directors effective October 31, 2025 after more than eight years of service, having joined in early 2017.

During her tenure the company grew from serving 30,000 members as a private firm to serving more than 100,000 seniors as a public company across multiple states. Clinton served on the Talent & Compensation Committee and the Nominating and Corporate Governance Committee. Company leaders thanked her for her guidance and emphasized continued commitment to a diverse, experienced Board to support Clover’s mission and growth.

Counterpart Health (Nasdaq: CLOV) released a whitepaper (Oct 30, 2025) showing its Counterpart Assistant (CA) tech helped primary care teams in high Area Deprivation Index neighborhoods detect chronic disease earlier and reduce hospital use.

Key results: diagnosis rates were higher for diabetes (+75%), CKD (+89%), CHF (+89%) and COPD (+70%); CKD detected at average Stage 2 vs 3A; diabetes A1C averaged 6.8% vs 7.1%; inpatient hospitalizations fell -7.6% to -21.2% and 30-day readmissions fell -11.5% to -20.8% across four diseases.

Clover Health (Nasdaq: CLOV) announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 11:00 a.m. Eastern Time.

A live webcast and replay will be available on Clover Health's investor relations website at https://investors.cloverhealth.com/.

Clover Health (Nasdaq: CLOV) announced its 2026 Medicare Advantage portfolio, preserving a comprehensive PPO lineup with $0 to low monthly premiums and Part B givebacks as Annual Enrollment Period opens Oct 15–Dec 7, 2025. The company says 100% of members will have stable or improved 2026 benefits and plans will be accessible to 5.2 million Medicare-eligible beneficiaries across 203 counties in 5 states. Clover credits its AI-powered Clover Assistant with earlier interventions—doctors start diabetes oral meds ~3 years earlier and diagnose CKD ~1.5 years earlier—and reports 32% YoY MA member growth.

Counterpart Health (CLOV) said its AI-driven HEDIS flywheel again powered Clover Health Medicare Advantage plans to top-tier results and made the platform available to third-party partners on Oct 14, 2025. Clover was the #1 performing PPO for HEDIS clinical quality measures among plans over 2,000 members and the only PPO in the Top 10. The flywheel combines point-of-care Counterpart Assistant prompts, real-time ingestion from 100+ data sources, NLP/LLM abstraction, and AI-augmented documentation closure to raise quality and reduce administrative burden.

Counterpart cites improved benchmark rates for screenings and diabetic eye exams and plans to scale the platform to more partners.

Clover Health (Nasdaq: CLOV) commented on CMS's 2026 Medicare Advantage Star ratings, reporting 3.5 Stars for its PPO MA plans and 4.0 Stars for its HMO MA plan; these ratings affect the 2027 payment year. The company reiterated confidence in driving above‑market membership growth and expanding Adjusted EBITDA profitability through 2027, citing AI‑driven improvements in its Clover Assistant and increased physician adoption. Clover reported H1 2025 revenue +34% and membership +32% year‑over‑year and a PPO HEDIS clinical score of 4.72.

Clover Health (Nasdaq: CLOV) will release its Third Quarter 2025 financial results after market close on Tuesday, November 4, 2025. Management will host a live webcast presentation at 5:00 p.m. Eastern Time the same day to discuss business and financial performance.

Investors can register for the webcast at the registration link provided and a live and archived replay will be available from Clover Health's Investor Relations website for 12 months.

Counterpart Health (Nasdaq: CLOV) announced two senior hires to accelerate enterprise partnerships and regional adoption of its AI‑powered platform Counterpart Assistant (CA). Blaine Lindsey joins as Vice President of Enterprise Growth and Partnerships to pursue national, risk‑bearing partnerships and convert inbound demand into strategic deployments. Shannon Jacobs becomes President of Market Operations for the Gulf Region to scale operations, launch new markets, and support clinicians in underserved, high‑need areas. The appointments target faster clinician adoption of AI insights within existing workflows to identify high‑risk patients and support value‑based care at scale.